Search results
Results from the WOW.Com Content Network
Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. [1] [2] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19. [1]
Schematic structure of an antibody–drug conjugate (ADC) Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [ 1 ] Unlike chemotherapy , ADCs are intended to target and kill tumor cells while sparing healthy cells.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells.
F5's originally offered application delivery controller (ADC) technology, [3] but expanded into application layer, automation, multi-cloud, and security services. As ransomware , data leaks , DDoS , and other attacks on businesses of all sizes are arising, companies such as F5 have continued to reinvent themselves. [ 4 ]
One of those stocks is Agree Realty (NYSE: ADC), which has gained about 14% during the past 12 months but still pays an attractive forward yield of 4.3%. ... For premium support please call: 800 ...
Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. [9] [11] [12] [13]
The transatlantic alliance reached a milestone in 2024 when all non-U.S. NATO allies spent the 2% target on average for the first time.
For premium support please call: 800-290-4726 ... I Asked 3 Food Editors To Name the Best Canned Tuna—They All Said the Same Brand ... so I asked a handful of food writers and editors about ...